EXPERIENCES WITH CHRONIC IDIOPATIC COUGH PATIENTS TREATED WITH LOW-DOSE ITRACONAZOLE - EXPERIENCES WITH CHRONIC IDIOPATIC COUGH PATIENTS TREATED WITH LOW-DOSE ITRACONAZOLE
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 8
Study Overview
Brief Summary
We selected 8 patients with CIC and carried out allergological examinations for Bjerkandera adusta (B. adusta), a BM fungus that has been shown to enhance cough severity. As adjunctive therapies, the patients were treated with oral prednisolone (10 mg/day) for 14 days after a 2-week observation period, and subsequently they received a low dose of ITCZ (50 mg/day) for 14 days. Clinical response to each treatment was monitored by the Japanese version of the Leicester Cough Questionnaire. We evaluated whether there was a recognizable clinical pattern that could distinguish ITCZ-responsive CIC (R-CIC) from ITCZ-non-responsive CIC (NR-CIC). (Results) Positive results for an immediate cutaneous reaction to B. adusta were observed in 4 patients in the R-CIC group (100%) and in 1 patient in the NR-CIC group (25.0%). The positive ratio for the skin test was significantly different between the groups (P<0.05). (Conclusions) Efficacy of ITCZ was demonstrated in a cluster of CIC patients. A positive result of immediate cutaneous reaction to B. adusta may aid in the successful management of CIC.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1)Patients having abnormal shadow on chest X-ray 2)Patients having wheezing audible 3)Patients having obstructive disorders in pulmonary function testing 4)Patients having severe complications 5)Patients having pulmonary tuberclosis 6)Jpatients without agreement 7)Patients being pregnant, possible pregnant or breast-feeding a baby 8)Patients judged inappropriate by attending physisians